Please ensure Javascript is enabled for purposes of website accessibility

Canopy Growth Strikes 2 Deals

By Eric Volkman - Oct 16, 2019 at 10:53AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company announced that it's closed its takeover of Beckley Canopy Therapeutics in the U.K. and jettisoned its AusCann stake in Australia.

Canopy Growth (CGC 4.76%), which is considered a leading marijuana stock, is reconfiguring itself with a pair of deals announced on Monday.

The first is the company's closing of its acquisition of U.K.-based Beckley Canopy Therapeutics. That entity, which focuses on the research of cannabis-based pharmaceuticals, was a joint venture it formed in 2018 with a think tank called Beckley Research & Innovation.

Two hands holding marijuana leaves against a blue sky.

Image source: Getty Images.

In addition to bringing Beckley Canopy Therapeutics fully into its portfolio, the closing of the deal also gives Canopy Growth 100% of Spectrum Biomedical UK. This company was formerly a joint venture between Canopy Growth and Beckley Canopy Therapeutics. Spectrum Biomedical UK is a distributor of Canopy Growth's medical cannabis offerings.

Canopy Growth first announced the purchase of the Beckley Canopy Therapeutics stake in August. It did not disclose the price or the terms of the deal at the time, nor did it do so in Monday's announcement.

In the announcement, Canopy Growth said that with those assets fully owned, they "will now be integrated into the broader Spectrum Therapeutics organization to increase the breadth of the clinical research being pursued under the Spectrum banner and to combine continental European and United Kingdom commercial teams."

Also on Monday, Canopy Growth announced it has entirely sold out of its stake in AusCann Group Holdings (ACNNF) in Australia.

This was effected with an off-market block trade for $0.15 per share. All told, Canopy Growth took in $6.3 million in gross proceeds from the sale. The company had owned a shareholding of just over 13% in AusCann, a producer of medical cannabis.

Canopy Growth says the divestment doesn't mean it's exiting Australia entirely or even fully divorcing its onetime holding. In the press release announcing the sale, the company said it "will allow us to sharpen our focus on our wholly owned operations in the market, while continuing to collaborate with our partners at AusCann."

Canopy Growth has a large cash position stemming from the huge investments plowed into it by alcoholic drinks maker Constellation Brands beginning in 2017. This has helped the company finance its numerous acquisitions. At the end of its most recently reported quarter, Canopy Growth had more than 1.8 billion Canadian dollars ($1.4 billion) in cash.

Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Constellation Brands. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Canopy Growth Stock Quote
Canopy Growth
CGC
$3.30 (4.76%) $0.15
AUSCANN GROUP HLDG NPV Stock Quote
AUSCANN GROUP HLDG NPV
ACNNF

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/13/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.